GEN Exclusives

More »

GEN News Highlights

More »
Dec 6, 2007

PTC and Spinal Muscular Atrophy Foundation Extend Agreement

  • PTC Therapeutics and the Spinal Muscular Atrophy Foundation agreed to expand their research collaboration to identify and characterized compounds to treat the disease.

    PTC will receive an additional $1.6 million in funding when certain milestone considerations are met.

    The partnerhip is focusing on candidates to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein, the absence of which causes SMA.

    “By applying our proprietary technologies,” says Stuart W. Peltz, Ph.D., president and CEO of PTC, “we have made important progress in our efforts to identify treatments for SMA.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?